These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1232529)

  • 1. The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma.
    Cuttner J; Wasserman LR; Martz G; Sonntag RW; Kyle RA; Silver RT; Spurr C; Harley JB; Wiernik PM; Cornwell GG; Falkson G; Glidewell O; Holland JF
    Med Pediatr Oncol; 1975; 1(3):207-16. PubMed ID: 1232529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine.
    Arch Intern Med; 1975 Jan; 135(1):157-62. PubMed ID: 1111464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for multiple myeloma.
    Alexanian R; Bonnet J; Gehan E; Haut A; Hewlett J; Lane M; Monto R; Wilson H
    Cancer; 1972 Aug; 30(2):382-9. PubMed ID: 5051662
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
    Chang HJ; Lee JH; Do YR; Bae SH; Lee JL; Nam SH; Yoon SS; Bang SM
    Korean J Intern Med; 2011 Dec; 26(4):403-9. PubMed ID: 22205840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmaintained remissions in multiple myeloma.
    Alexanian R; Gehan E; Haut A; Saiki J; Weick J
    Blood; 1978 Jun; 51(6):1005-11. PubMed ID: 647110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone healing in multiple myeloma with melphalan chemotherapy.
    Rodriguez LH; Finkelstein JB; Shullenberger CC; Alexanian R
    Ann Intern Med; 1972 Apr; 76(4):551-6. PubMed ID: 4640313
    [No Abstract]   [Full Text] [Related]  

  • 10. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
    Ahre A; Björkholm M; Mellstedt H; Holm G; Brenning G; Engstedt L; Gahrton G; Hällen J; Johansson B; Johansson SG; Karnström L; Killander A; Lerner R; Lockner D; Lönnqvist B; Simonsson B; Stalfelt AM; Ternstedt B; Wadman B
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):499-506. PubMed ID: 6345174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose intensity analysis of melphalan and prednisone in multiple myeloma.
    Palmer M; Belch A; Hanson J; Brox L
    J Natl Cancer Inst; 1988 May; 80(6):414-8. PubMed ID: 3367382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
    Pulsoni A; Villivà N; Cavalieri E; Falcucci P; La Verde G; Matera R; Petrucci MT; Tosti ME; Mandelli F
    Drugs Aging; 2002; 19(12):947-53. PubMed ID: 12495369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
    Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response rate and survival in myeloma patients receiving prednisone alone.
    McIntyre OR; Pajak TF; Kyle RA; Cornwell GG; Leone L
    Med Pediatr Oncol; 1985; 13(5):239-43. PubMed ID: 4033539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma. II. The value of melphalan.
    Bernard DB; Lynch SR; Bothwell TH; Bezwoda WR; Stevens K; Shulman G
    S Afr Med J; 1974 May; 48(24):1026-8. PubMed ID: 4835772
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
    Mateos MV; Richardson PG; Dimopoulos MA; Palumbo A; Anderson KC; Shi H; Elliott J; Dow E; van de Velde H; Niculescu L; San Miguel JF
    Am J Hematol; 2015 Apr; 90(4):314-9. PubMed ID: 25557740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.